Posted On: 02/15/2021 12:12:54 PM Posted By: Ke
Post# of 148190
(Total Views: 441)
Posted On: 02/15/2021 12:21:05 PM
Posted On: 02/15/2021 12:12:54 PM
Posted By: KenChowder
Re: CDiddy #77982
“I also believe that doctors will realize that Leron can be enormously helpful for moderate patients as well. You want to prevent them from becoming severe, keep them out of the hospital? Give a moderate a shot. Offlabel maybe, but I think it will happen.”
Once leronlimab is approved for the S/C population, and the LH trial has started, I don’t see why CYDY wouldn’t start a pivotal trial for the M2M population based on the findings from the phase 2 trial. Demand for leronlimab would nearly double after a pivotal phase 3 for the M2M population demonstrated a 50% or higher reduction in progression from M2M to S/C. Big market there, not only for 2021, but for years to come.
Posted By: KenChowder
Re: CDiddy #77982
“I also believe that doctors will realize that Leron can be enormously helpful for moderate patients as well. You want to prevent them from becoming severe, keep them out of the hospital? Give a moderate a shot. Offlabel maybe, but I think it will happen.”
Once leronlimab is approved for the S/C population, and the LH trial has started, I don’t see why CYDY wouldn’t start a pivotal trial for the M2M population based on the findings from the phase 2 trial. Demand for leronlimab would nearly double after a pivotal phase 3 for the M2M population demonstrated a 50% or higher reduction in progression from M2M to S/C. Big market there, not only for 2021, but for years to come.
(4)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼